Discovery Pipeline
  • Development of aldosterone synthase inhibitors

    Aldosterone synthase inhibitor is one of the most anticipated drug in cardio-metabolic therapy. We develop compounds that selectively inhibit synthesis of aldosterone for future use in therapy of drug-resistant arterial hypertension and non-genomiс effects of high aldosterone. We are the first to fulfill this gap by solving the crystal structure of aldosterone synthase in complex with substrate and inhibitor.

    read more
  • Anti-tuberculosis drug discovery

    We’ve identified and validated a new targets – mycobacterial cytochromes P450, responsible for cell wall formation and depression of local immune response in human. This achievement is a basis for a drug discovery for treatment of resistant (MDR, XDR) forms of tuberculosis. 

    read more
  • Potential for a future pipeline

    Rare diseases, fungal infections and cancer are an examples of our potential to extend our pipeline future.

    read more
News and Events
07 November 2016
BIO-Europe 2016
Target Medicals in participating at the BIO-Europe 2016 conference.
22 July 2016
StartUp Village 2016 winners
Target medicals joined the ranks of the contest «StartUp Village 2016» Winners
09 November 2015
Target Medicals is among finalists of BiotechMed GenerationS (Tomsk)
A demo day of BiotechMed GenerationS was held in Tomsk, where the 5 finalists of the track were determined.
All news and events